Value of determining the cerebrospinal fluid protein markers of amyloidosis and neurodegeneration in the diagnosis of vascular and neurodegenerative cognitive impairments

The article presents data on different forms of moderate cognitive impairments (MCI) and the specific features of their transformation to dementia. Cerebrospinal fluid (CSF) was investigated in 60 patients with the amnestic and neurodynamic types of MCI, in 15 patients with vascular dementia (VD), 50 patients with Alzheimer’s disease (AD), and 23 patients with mixed vascular and neurodegenerative dementia (MVND). The specific features of β-amyloid and τ-protein concentrations were established in the preclinical stages of dementia, which reflects the main components of the pathogenesis of neurodegeneration. In the amnestic form of MCI and AD, there was drastically decreased Aβ-42 and increased τ-protein levels in SCF. As cognitive impairments progressed, there was a rise in the concentration of τ-protein; its level correlated with the severity of dementia. In MND, the level of Aβ-42 was significantly reduced while the concentration of τ-protein was much increased; moreover, to a greater extent than in AD and VD. Cerebrovascular damage and neurodegeneration were related to each other and mutually worsened clinical and pathogenic effects.

1. <div><p>World Health Organization. Dementia: A public health priority. Geneva: World Health Organization; 2012.</p><p>Mayeux R. Epidemiology of neurodegeneration. Annual Rev. Neurosci. 2003;25(6):81–104. DOI: http://dx.doi.org/10.1146/annurev.neuro.26.043002.094919</p><p>Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005:366(9503):2112–7. DOI: http://dx.doi.org/10.1016/S0140-6736(05)67889-0.</p><p>Емелин АЮ. Когнитивные нарушения при цереброваскулярной болезни. Дис. … докт. мед. наук. Санкт-Петербург; 2010. 413 с. [Emelin AYu. Kognitivnye narusheniya pri tserebrovaskulyarnoy bolezni. Dis. … dokt. med. nauk. St-Petersburg; 2010. 413 p.]</p><p>Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun study. JAMA. 1997;277(10):813–817. DOI: http://dx.doi.org/10.1001/jama.1997.03540340047031</p><p>Парфенов ВА, Старчина ЮА. Когнитивные расстройства и их лечение у больных артериальной гипертензией. Русский медицинский журнал. 2007;15(2):117–21. [Parfenov VA, Starchina YuA. Kognitivnye rasstroystva i ikh lechenie u bol'nykh arterial'noy gipertenziey. Russkiy meditsinskiy zhurnal. 2007;15(2):117–21.]</p><p>Лобзин В.Ю., Одинак М.М., Емелин А.Ю. Сосудистая деменция. Вестник Российской военно-медицинской академии. 2004:1(11);120–4. [Lobzin V.Yu., Odinak M.M., Emelin A.Yu. Sosudistaya dementsiya. Vestnik Rossiyskoy voenno-meditsinskoy akademii. 2004:1(11);120–4.]</p><p>Левин ОС, Голубева ЛВ. Гетерогенность умеренного когнитивного расстройства: диагностические и терапевтические аспекты. Консилиум. 2006;8(2):106–10. [Levin OS, Golubeva LV. Geterogennost' umerennogo kognitivnogo rasstroystva: diagnosticheskie i terapevticheskie aspekty. Konsilium. 2006;8(2):106–10.]</p><p>Дамулин ИВ. Легкие когнитивные нарушения. Сonsilium medicum. 2004;6(2):149–53. [Damulin IV. Legkie kognitivnye narusheniya. Sonsilium medicum. 2004;6(2):149–53.]</p><p>Иллариошкин СН. Ранние (додементные) формы когнитивных расстройств. Consilium Medicum. 2007:9(2):107–11. [Illarioshkin SN. Rannie (dodementnye) formy kognitivnykh rasstroystv. Consilium Medicum. 2007:9(2):107–11.]</p><p>Nordlund A, Rolstad S, Klang O et al. Two year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J Neurol Neurosurg Psychiatry. 2010;81(5):541–6. DOI: http://dx.doi.org/10.1136/jnnp.2008.171066.</p><p>Meyer J, Xu C, Thornby J et al. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer’s disease? Stroke. 2002:33(8):1981–5. DOI: http://dx.doi.org/10.1161/01.STR.0000024432.34557.10.</p><p>Rasquin SM, Lodder J, Visser PJ et al. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2–year follow–up study. Dement Geriatr Cogn Disord. 2005:19(2–3):113–9. DOI: http://dx.doi.org/10.1159/000082662.</p><p>Левин ОС. Диагностика и лечение деменции в клинической практике. Москва: МЕДпресс–информ; 2009. 256 с. [Levin OS. Diagnostika i lechenie dementsii v klinicheskoy praktike. Moskva: MEDpress–inform; 2009. 256 p.]</p><p>Одинак ММ, Емелин АЮ, Лобзин ВЮ и др. Современные возможности нейровизуализации в дифференциальной диагностике когнитивных нарушений. Неврология, нейропсихиатрия, психосоматика. Спецвыпуск «Когнитивные и другие нервно-психические расстройства». 2012:(2):51–5. [Odinak MM, Emelin AYu, Lobzin VYu et al. Current capacities for neuroimaging in the differential diagnosis of cognitive impairments. Neurology, Neuropsychiatry, Psychosomatics. Spetsvypusk «Kognitivnye i drugie nervno-psikhicheskie rasstroystva». 2012:(2):51–5.]</p><p>He J, Farias S, Martinez O et al. Differences of brain volume, hippocampal volume, cerebrovascular risk factors and APOE4 among MCI subtypes. Arch Neurol. 2009:66(11):1393–9. DOI: http://dx.doi.org/10.1001/archneurol.2009.252.</p><p>Dubois B, Feldman HH, Jzcova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–46. DOI: http://dx.doi.org/10.1016/S1474-4422(07)70178-3.</p><p>Riverol M, Lopez O. Biomarkers in Alzheimer’s disease. Front Neurol. 2011;2:46.</p><p>Shoji M. Biomarkers of the dementia. Int J Alzheimers Dis. 2011;2011:Article ID 564321, 7 p.</p><p>Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–34. DOI: http://dx.doi.org/10.1016/S1474-4422(06)70355-6.</p><p>Успенская ОВ, Яхно НН, Белушкина НН. Нейрохимические маркеры нейродегенерации в ранней диагностике болезни Альцгеймера, сосудистой и смешанной деменции. Журнал неврологии и психиатрии им С.С. Корсакова. 2010;110(8):36–40. [Uspenskaia OV, Iakhno NN, Belushkina NN. Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(8):36–40.]</p><p>Лобзин ВЮ, Емелин АЮ. Снижение концентрации Аβ-42 амилоидного белка в цереброспинальной жидкости - предиктор развития деменции. Вестник Российской Военно-медицинской академии. Прил. № 2. Санкт-Петербург: ВМедА, 2013;4(44):77–8. [Lobzin VYu, Emelin AYu. Snizhenie kontsentratsii Aβ-42 amiloidnogo belka v tserebrospinal'noy zhidkosti - prediktor razvitiya dementsii. Vestnik Rossiyskoy Voenno-meditsinskoy akademii. Suppl 2. St-Petersburg: VMedA, 2013;4(44):77–8.</p><p>Prvulovic D, Hampel H. Amyloid β (Aβ) and phosphor-tau (p-tau) as diagnostic biomarkers in Alzheimer’s disease. Clin Chem Lab Med. 2011;49(3):367–74. DOI: http://dx.doi.org/10.1515/CCLM.2011.087.</p><p>Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385–93. DOI: http://dx.doi.org/10.1001/jama.2009.1064.</p><p>Visser P, Verhey F, Knol D et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619–27. DOI: http://dx.doi.org/10.1016/S1474-4422(09)70139-5.</p><p>Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403–13. DOI: http://dx.doi.org/10.1002/ana.21610.</p><p>Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using β-amyloid (1-42) and tau-levels in CSF. Neurology. 1999;52(8):1555–62. DOI: http://dx.doi.org/10.1212/WNL.52.8.1555.</p><p>Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54(4):827–32. DOI: http://dx.doi.org/10.1212/WNL.54.4.827.</p><p>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. DOI: http://dx.doi.org/10.1016/0022-3956(75)90026-6.</p><p>Dubois B, Slachevsky A, Litvan I et al. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621–6. DOI: http://dx.doi.org/10.1212/WNL.55.11.1621.</p><p>Sunderland T. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriatr Soc. 1989;37(8):725–9.</p><p>Лурия АР. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. 2-е доп. изд. Москва: Издательство МГУ; 1969. 504 с. [Luriya AR. Vysshie korkovye funktsii cheloveka i ikh narusheniya pri lokal'nykh porazheniyakh mozga. 2-e dop. izd. Mosсow: Izdatel'stvo MGU; 1969. 504 p.]</p><p>Grober E, Buschke H, Crystal H et al. Screening for dementia by memory testing. Neurology. 1988;38(6):900–3. DOI: http://dx.doi.org/10.1212/WNL.38.6.900.</p><p>Smith A. Symbol–digit modalities test (SDMT) manual. - Los Angeles: Western psychological services; 1982. 14 p.</p><p>Kazdin A.E. Single-case research designs: methods for clinical and applied settings. New York: Oxford University Press; 1982. 55 p.</p><p>Wechsler DA. Standardized memory scale for clinical use. J Psychol. 1945;19(1):87–95. DOI: http://dx.doi.org/10.1080/00223980.1945.9917223.</p><p>Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. DOI: http://dx.doi.org/10.1111/j.1532-5415.2005.53221.x.</p><p>Hughes CP, Berg L, Danziger WL et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72. DOI: http://dx.doi.org/10.1192/bjp.140.6.566.</p><p>Mattis S. Mental status examination for organic mental syndrome in the elderly patient in geriatric psychiatry. In: Bellak L, Karasu TB, editors. Geriatric psychiatry: a hand book for psychiatrists and primary care physicians. New York: Grune and Stratton; 1976. P. 77–121.</p><p>Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer’s disease. J Mol Neurosci. 2012;47(1):1–14. DOI: http://dx.doi.org/10.1007/s12031-011-9665-5.</p></div><br />